Buy
Sell
Share Name Share Symbol Market Type Share ISIN Share Description
Salvarx Group Plc LSE:SALV London Ordinary Share IM00BZ4SS228 ORD 2.5P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  0.00 0.0% 4.50 - 0.00 01:00:00
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Health Care Equipment & Services 0.0 -0.5 1.0 4.5 2

Salvarx Share Discussion Threads

Showing 476 to 499 of 500 messages
Chat Pages: 20  19  18  17  16  15  14  13  12  11  10  9  Older
DateSubjectAuthorDiscuss
18/9/2020
12:58
The Intensity tweet came out after market close I don't pay too much attention to PTGEF share price It is only worth bothering with once on NASDAQ There is a reason Management want to get it on NASDAQ There is a biotech gold rush going on and you want to be part of it In an industry worth over $200bn a year (that's just cancer drugs not all Pharma) it doesn't really matter how many players there are there is a big enough and growing enough cake
the stigologist
18/9/2020
12:36
Hi Stig I'm still holding my Portage and these. Portage seem to be adrift in a melee of amazing potential and regulatory failings (depending who you believe). For Salvarx, I now have a share certificate for an unlisted private company of indeterminable value. Feels like there are far too many companies chasing the same pot of gold. Only one of them will get it and some of them are much larger businesses than Portage with much deeper pockets. That announcement yesterday didn't seem to do much for the Portage share price (which went down 5%?) Perhaps this will all come good - but I'm not getting too excited just in case it doesn't !!
dexdringle
18/9/2020
00:57
htTps://intensitytherapeutics.com/intensity-therapeutics-doses-first-patient-with-combination-of-int230-6-and-bristol-myers-squibbs-yervoy-in-a-phase-2-study/
the stigologist
05/7/2020
22:33
Yes. And even allowing for currency. I got a letter from Share.com post consolidation and was surprised. Haven't really kept up to date with goings on re Portage. SALV was my main play.
the stigologist
05/7/2020
22:11
Even allowing for the consolidation?
bscuit
05/7/2020
21:29
Didn't realise I had so many Portage shares. Nice surprise
the stigologist
25/6/2020
13:22
Intensity Therapeutics Announces Publication of Research Reporting that Intratumoral Administration of INT230-6 Demonstrates Tissue Dispersive Properties, Tumor Regression and Elicits Systemic Adaptive Immunity In vivo research published in a special issue of the International Journal of Molecular Sciences WESTPORT, Conn.--(BUSINESS WIRE)-- Intensity Therapeutics, Inc., a clinical-stage biotechnology company pioneering a novel, immune-based drug approach to treat solid tumor cancers through direct tumor injection, today announced the publication of results from the Company’s nonclinical research in the International Journal of Molecular Sciences (IJMS). The paper titled, “Intratumoral Administration of a Novel Cytotoxic Formulation with Strong Tissue Dispersive Properties Regresses Tumor Growth and Elicits Systemic Adaptive Immunity in In Vivo Models,” was published in IJMS as part of a Special Issue titled The Immune Landscape in Solid Tumors. The Special Issue addresses various aspects of the molecular and cellular biology of immune cells in the context of tumors and invites experts in the field to contribute an original research article or a comprehensive review. The paper is available online (doi.org/10.3390/ijms21124493). The paper describes the Company’s lead product candidate, INT230-6, a novel combination of cisplatin and vinblastine formulated with a unique amphiphilic diffusion enhancer molecule (SHAO) that non-covalently interacts with payloads to increase intratumoral (IT) drug dispersion when injected into solid tumors. The data reported demonstrated that INT230-6 achieved greater inhibition of tumor growth and improved survival compared to the same drugs without enhancer given intravenously or IT. INT230-6 treatment increased the number of immune infiltrating cells within injected tumors. Animals demonstrating complete responses developed systemic immunity to the cancer. INT230-6 when combined with anti-programmed cell death protein 1 (PD-1), antibodies resulted in improved survival and increased rate of complete responses. INT230-6 induced significant tumor necrosis, which induced a systemic immune-based anti-cancer attack. This research demonstrates a novel, local treatment approach for cancer that minimizes systemic toxicity while stimulating adaptive immunity. “The results reported in the paper provided the pre-clinical rationale to advance INT230-6 into clinical development,” said Lewis H. Bender Founder, President and CEO of Intensity Therapeutics and lead author on the paper. “Our clinical research conducted to-date is consistent with the results of this paper; data suggests that the dispersion, tumor-killing and immune activation properties of INT230-6 observed in mice are translating to humans. We are looking forward to initiating phase 2 clinical cohorts later this year combining INT230-6 with our partners’ products, Merck's pembrolizumab and Bristol Myers Squibb's ipilimumab, in cancers with high unmet medical need.”
abadan2
17/6/2020
15:22
Never understood why SALV was kept alive with its holding of the remainder of the Portage shares. Seems totally pointless. The 'plan' to keep the listing and reverse takeover another business (or whatever) never happened so we were de-listed. I now have a useless share certificate for my holding in the now private Salvarx. Perhaps if Portage takes off, they can sell the holding, make a final cash distribution to shareholders and wind Salvarx up once and for all ?
dexdringle
17/6/2020
14:38
100- 1 consolidation taken place
bscuit
17/6/2020
14:02
Portage got more funding Jim Mellon backstopping deal
the stigologist
13/5/2020
16:41
CSE, now 16%
bobby.ifa
13/5/2020
16:02
OTC or CSE?
bscuit
13/5/2020
15:17
Portage up 12.5%, 13-13.5p
bobby.ifa
03/5/2020
00:32
Uninvestable on pink sheets or CSE in my opinion If they're going to list on Nasdaq get on on with it
the stigologist
03/5/2020
00:27
CSE, though at present most action on OTC Pink in USA
bscuit
19/4/2020
11:40
Are they listed on tradeable exchange?
bobby.ifa
19/4/2020
11:07
Interesting
the stigologist
19/4/2020
10:51
Portage Biotech : provides update on portfolio company, Intensity Therapeutics, Inc. 0 04/15/2020 | 01:18pm BST TORONTO, April 15, 2020 /PRNewswire/ - (PBT.U: CSE, PTGEF: OTC Markets) - Portage Biotech Inc. ("Portage" or the "Company") wishes to provide an update on a portfolio company, Intensity Therapeutics, Inc. ("Intensity"). Portage Biotech Inc. holds an 9.7% equity interest in Intensity. Intensity signs clinical trial collaboration with Bristol Myers Squibb Intensity's collaboration with Merck reports favorable safety of INT230-6 in combination with pembrolizumab The company is launching seven phase 2 combination cohorts in solid tumors Intensity Therapeutics announced yesterday it has entered into a clinical trial collaboration agreement with Bristol Myers Squibb Company (NYSE: BMY). The program will evaluate the safety and efficacy of Intensity's lead product INT230-6, an investigational, novel and potent anti-cancer drug designed to directly kill cancer cells through intratumoral injection and improve immune cell recognition of cancer, when dosed in combination with Bristol Myers Squibb's Cytotoxic T Lymphocyte-Associated Antigen 4 (CTLA-4) immune checkpoint inhibitor Yervoy® (ipilimumab). The combination will be evaluated in patients with breast cancer, liver cancer and advanced sarcoma in a series of new cohorts within IT-01, Intensity's ongoing Phase 1/2 clinical trial. Intensity will sponsor and conduct the clinical trial and Bristol Myers Squibb will supply Yervoy for use in the study. "We are pleased to share that Intensity has now partnered with Merck (previously announced on June 25th 2019) and BMS, the two leaders in the cancer immunotherapy space" said Ian B. Walters, MD, CEO of Portage and Chief Medical Officer of Intensity. Recently (March 14, 2020) Intensity also announced favorable safety from the first cohort of the Keynote A10 study (pembrolizumab/anti-PD1 plus Intensity's INT230-6). Intensity is launching into seven phase 2 programs evaluating high unmet medical need tumors types such as colorectal, pancreatic, squamous cell, bile duct, sarcoma, liver and breast cancers. The full release can be found at: hxxps://intensitytherapeutics.com/media/#media-group-press-releases So working with both Merck and BMS!
abadan2
06/3/2020
00:58
it's illiquid and on an OTC exchange. Price can't be taken seriously. Intensity have been tweeting again recently though
the stigologist
06/3/2020
00:36
P on the move? Closed up 15% @.15
bscuit
25/1/2020
10:58
I'm sure we will.
the stigologist
25/1/2020
10:46
Will also increase the value of the Portage shares retained by the old (now delisted) Salvarx. I wonder whether we will ever get to extract our value from that?
dexdringle
25/1/2020
10:38
Hearing excited chatter re Portage Biotech and Nasdaq listing
the stigologist
03/1/2020
19:16
OTC price today $0.12 meaning unless I am wrong for each SAlV share 18 Portage shares x .12 divided by 1.31 (US$/£ exchange rate) or amI missing something?
bscuit
Chat Pages: 20  19  18  17  16  15  14  13  12  11  10  9  Older
ADVFN Advertorial
Your Recent History
LSE
SALV
Salvarx
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V: D:20200921 03:39:46